BNB Plus (BNBX) investor relations material

Executive summary

• Shifted focus to a digital asset treasury strategy centered on BNB, the Binance blockchain's native cryptocurrency, following a major restructuring and workforce reduction of 60% completed by December 2025.

• LineaRx subsidiary continues to commercialize nucleic acid production solutions for biopharma and diagnostics, while DNA Tagging and Security Products and MDx Testing Services are being wound down or reported as discontinued.

Financial highlights

• For the three months ended March 31, 2026, total revenues were $1,024,111, up 4% year-over-year, with product revenues up 84% and service revenues down 92%.

• Gross profit increased 109% to $826,786, with gross margin rising to 81% from 52% year-over-year.

• Net loss for the quarter was $6,665,159, compared to $3,336,120 in the prior year period.

• For the six months ended March 31, 2026, net loss was $25,271,341, up from $6,004,833 year-over-year.

• Operating cash flow was negative $7,594,751 for the six months ended March 31, 2026.

• Accumulated deficit reached $404,451,992 as of March 31, 2026.

Outlook and guidance

• Management estimates sufficient cash, cash equivalents, and liquid cryptocurrency to fund operations for the next twelve months.

• DAT (digital asset treasury) is considered a long-term investment, with no plans to liquidate for working capital needs in the near term.